Haleon (LON:HLN) Announces Earnings Results

Haleon (LON:HLN) issued its quarterly earnings data on Thursday. The company reported GBX 18.60 EPS for the quarter, Digital Look Earnings reports. Haleon had a net margin of 9.66% and a return on equity of 6.54%.

Haleon Price Performance

Shares of HLN stock traded up GBX 15.30 on Thursday, reaching GBX 393.20. The company’s stock had a trading volume of 33,161,078 shares, compared to its average volume of 39,735,855. The stock’s fifty day simple moving average is GBX 382.12 and its 200-day simple moving average is GBX 364.77. Haleon has a 1 year low of GBX 325.10 and a 1 year high of GBX 419.50. The company has a market capitalization of £35.02 billion, a price-to-earnings ratio of 23.54, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. The company has a current ratio of 0.84, a quick ratio of 0.93 and a debt-to-equity ratio of 53.36.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HLN shares. JPMorgan Chase & Co. raised their price objective on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Berenberg Bank lifted their target price on Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Jefferies Financial Group reissued a “buy” rating and issued a GBX 450 price objective on shares of Haleon in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research report on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 407.83.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.